AR071910A1 - Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. - Google Patents

Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.

Info

Publication number
AR071910A1
AR071910A1 ARP090101881A ARP090101881A AR071910A1 AR 071910 A1 AR071910 A1 AR 071910A1 AR P090101881 A ARP090101881 A AR P090101881A AR P090101881 A ARP090101881 A AR P090101881A AR 071910 A1 AR071910 A1 AR 071910A1
Authority
AR
Argentina
Prior art keywords
hpv
vaccine
measles
recombinant
hpv6
Prior art date
Application number
ARP090101881A
Other languages
English (en)
Inventor
Francesca Scuderi
Martin Billeter
Sanjeev K Mendiretta
Reinhard Glueck
Viviana Gianino
Giuseppina Cantarella
Agata Fazio
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AR071910A1 publication Critical patent/AR071910A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Abstract

Vacunas combinadas contra el sarampion y el virus del papiloma humano (HPV). Vectores del virus de sarampion recombinantes que contienen  cido nucleico heterologo que codifica uno o varios ant¡genos derivados del HPV, preferentemente, el ant¡geno L1 de la c pside mayor, el ant¡geno L2 de la c pside menor, oncoprote¡nas del gen temprano E6 y gen temprano E7 del HPV tipo 16, y opcionalmente de los tipos 18, 6 y 11. En una primera realizacion, las vacunas profil cticas se generan expresando ant¡genos HPV, preferentemente L1 y/o L2. En otra realizacion, las vacunas terapeuticas se generan expresando prote¡nas E6 y E7, y opcionalmente L1 y L2. Reivindicacion 1: Una vacuna para el sarampion y el HPV combinada caracterizada porque comprende los virus de la vacuna para el sarampion recombinados que expresan ant¡genos HPV capaces de sacar una respuesta inmunologica y proporcionar proteccion contra el sarampion y el HPV, Reivindicacion 11: Un vector caracterizado porque comprende la secuencia de nucleotidos de ant¡genos de diferentes tipos de HPV y sarampion. Reivindicacion 14: El vector tal como se reivindica en la reivindicacion 11, caracterizado porque el ant¡geno se selecciona de prote¡nas L1 o L2 o E6 o E7 de HPV-16, HPV-18, HPV-6 y HPV-11. Reivindicacion 23: La vacuna tal como se reivindica en cualquiera de las reivindicaciones precedentes caracterizada porque comprende el virus del sarampion recombinante que tiene insertada una secuencia de  cido nucleico que codifica el HPV16-L1 o HPV18-L1 o HPV6-L1 o HPV11-L1 o HPV16-L2 o HPV18-L2 o HPV6-L2 o HPV11-L2 o HPV1I6-E6 o HPV18-E6 o HPV6-E6 o HPV16-E7 o HPV18-E7 o HPV6-E7 o cualquiera de sus combinaciones. Reivindicacion 27: Una vacuna tal corno se reivindica en la reivindicacion 25, caracterizada porque el adyuvante es una interleuquina, preferentemente interleuquina 2. Reivindicacion 28 :Una vacuna tal como se reivindica en cualquiera de las reivindicaciones precedentes, caracterizada porque la vacuna consiste esencialmente de al menos uno de los virus del HPV y el sarampion recombinantes o una mezcla de dos o varios de tales virus. Reivindicacion 34: Una vacuna tal corno se reivindica en las reivindicaciones precedentes es un componente de una vacuna combinada caracterizada porque los otros componentes son virus de rubeola, paperas, varicela u otro virus de vacuna atenuada viva, atenuada naturalmente o recombinante, solos o combinados.
ARP090101881A 2008-05-26 2009-05-26 Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. AR071910A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1113MU2008 2008-05-26

Publications (1)

Publication Number Publication Date
AR071910A1 true AR071910A1 (es) 2010-07-21

Family

ID=42316922

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101881A AR071910A1 (es) 2008-05-26 2009-05-26 Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.

Country Status (13)

Country Link
US (1) US9623098B2 (es)
EP (1) EP2280728B1 (es)
JP (1) JP5726727B2 (es)
CN (2) CN106377767A (es)
AR (1) AR071910A1 (es)
AU (1) AU2009336562B2 (es)
BR (1) BRPI0909547A2 (es)
CA (1) CA2722847C (es)
EA (1) EA027784B1 (es)
ES (1) ES2565846T3 (es)
TW (1) TWI561244B (es)
WO (1) WO2010079505A2 (es)
ZA (1) ZA201007595B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075277A1 (en) 2000-03-31 2001-10-11 Northern Research And Engineering Corporation Solid-fueled power generation system with carbon dioxide sequestration and method therefor
DK1375512T3 (da) * 2002-06-20 2009-10-26 Pasteur Institut Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger
DK1375670T3 (da) 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
UA104180C2 (uk) * 2009-05-05 2014-01-10 Каділа Хелткере Лімітед Комбінована вакцина проти кору та малярії
KR102216962B1 (ko) * 2011-10-12 2021-02-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법
US20130122038A1 (en) * 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
CN114181961A (zh) 2013-03-12 2022-03-15 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的改进疫苗及其使用方法
CN105801704B (zh) * 2014-12-31 2020-06-02 艾托金生物医药（苏州）有限公司 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用
CN104830869B (zh) * 2015-04-30 2018-06-01 武汉凯德维斯生物技术有限公司 与宫颈癌发生相关的hpv整合的基因位点及其应用
US10550164B2 (en) 2015-08-03 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use
RU2681174C1 (ru) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE122007000084I1 (de) 1991-07-19 2008-03-27 Univ Queensland St Lucia Impfstoff gegen Humanes Papillomavirus (Typ 18)
ATE380871T1 (de) 1992-06-25 2007-12-15 Univ Georgetown Papillomavirus vakzine
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE122011100018I1 (de) 1993-03-09 2011-11-17 Univ Rochester Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
DK0780475T4 (da) 1995-08-09 2006-10-23 Schweiz Serum & Impfinst Fremgangsmåde til fremstilling af infektiöse negativ-streng RNA-virus
PL343429A1 (en) * 1998-03-09 2001-08-13 Smithkline Beecham Biolog Combined vaccine compositions
US7357936B1 (en) * 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
DK1375670T3 (da) * 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
CN1756845A (zh) 2002-11-12 2006-04-05 A·B·德塞罗斯 腺病毒载体疫苗
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
WO2007120120A2 (en) * 2005-01-12 2007-10-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human parainfluenza virus, methods and uses thereof

Also Published As

Publication number Publication date
CA2722847C (en) 2019-12-17
CN106377767A (zh) 2017-02-08
CA2722847A1 (en) 2010-07-15
WO2010079505A2 (en) 2010-07-15
EP2280728A2 (en) 2011-02-09
EA201071366A1 (ru) 2011-06-30
ES2565846T3 (es) 2016-04-07
AU2009336562B2 (en) 2012-12-20
JP2011524863A (ja) 2011-09-08
WO2010079505A3 (en) 2010-11-04
TWI561244B (en) 2016-12-11
US9623098B2 (en) 2017-04-18
CN102099053A (zh) 2011-06-15
TW201010718A (en) 2010-03-16
ZA201007595B (en) 2011-09-28
AU2009336562A1 (en) 2010-07-15
JP5726727B2 (ja) 2015-06-03
US20110129493A1 (en) 2011-06-02
BRPI0909547A2 (pt) 2019-03-06
EA027784B1 (ru) 2017-09-29
EP2280728B1 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
AR071910A1 (es) Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.
CY1124618T1 (el) Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
EA201492110A1 (ru) Вакцины против впг-2
MX344069B (es) Vacuna vectorizada por el herpesvirus de los pavos contra la influenza aviar en aves de corral.
MX2014007516A (es) Procesos que utilizan vlps con capsides resistentes a hidrolasas.
EP3156070A3 (en) Newcastle disease virus vectored herpesvirus vaccines
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
MX2009012597A (es) Poxvirus de mapache que expresa glicoproteinas de la rabia.
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
UY33523A (es) ?vectores de parapoxvirus?.
CO6670515A2 (es) Vectores de parapoxvirus
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
AR109540A1 (es) Moléculas promotoras para expresar antígenos virales
EA201691120A1 (ru) Векторные композиции и способы индукции усиленного иммунного ответа с использованием векторов поксвируса
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
PH12020500526A1 (en) Paramyxoviridae expression system
MX2017014417A (es) Vacunas contra el dengue.
EA201992602A3 (ru) Вакцины против впг-2

Legal Events

Date Code Title Description
FB Suspension of granting procedure